Bioactive Natural Products and Synthetic Small Molecules as Potential Investigational Treatments for Neurodegenerative Diseases

Dear Colleagues,

The prevalence of Alzheimer’s disease (AD) is continuously growing worldwide, which leads to great social–economic burdens. Despite the great therapeutic improvement researchers have achieved in the past few decades, novel treatments targeting Alzheimer’s disease remain an urgent need.

AD is a progressive neurodegenerative disorder, and patients are characterized by dysfunctions of behaviors, memories, and spatial awareness and, in the late stage, loss of ability to participate in general activities. The neuropathology may involve protein abnormalities of neurofibrillary tangles of tau proteins and senile amyloid plaques of amyloid b peptides (Ab), and neuronal and synaptic losses and accompanying lower levels of acetylcholine, inflammations, and oxidative damages. The “amyloid hypothesis” is the main AD etiology for the imbalance of production and clearance of Ab, which aggregates and then accumulates to initiate AD progress. Reactive oxygen species (ROS) and free radicals are associated with aging based on the “free radical theory of aging”. Although researchers have devoted themselves to developing small molecules and monoclonal antibodies as AD treatments in recent decades, none so far have been clinically successful in cognition improvement. The poor outcome is due to the multifactorial pathogenetic mechanism of AD, and to date, the only approved therapeutic drugs for clinical AD treatments are acetylcholinesterase (AChE) inhibitors, which are developed based on the “cholinergic hypothesis”, and one N-methyl-D-aspartate (NMDA) receptor antagonist. While these drugs have shown short-term benefits in improving symptoms, however, they have not been found to be able to reverse or delay AD progression. This clearly indicates that an unmet medical need exists in AD.

The scope of this Research Topic is to investigate the potential efficacy, pharmacokinetics, and underlying mechanisms of natural products or synthetic compounds against Alzheimer’s disease using modern tools on the following subtopics but not limited to:

Subtopics:

• Small molecular drugs and medicinal plants potentially against Alzheimer’s disease, and the in vivo pharmacokinetic properties;
• AChE inhibitory assay and molecular docking with AChE;
• Ab aggregation, tau protein hyperphosphorylation and neurofibrillary tangles, reactive oxygen species, neuron or microglia inflammation and their roles in neurodegeneration in cell or animal models;
• In vitro and/or in vivo models studying natural products, synthetic compounds, or derivatives.

You may choose our Joint Special Issue in CIMB.

Prof. Dr. Wen-Chi Hou
Dr. Rita P.-Y. Chen
Prof. Dr. Wei-Jan Huang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• Alzheimer’s disease
• amyloid beta
• antioxidant
• reactive oxygen species
• tau protein
• cell line experiment
• animal models
• bioactive natural products
• synthetic compounds or derivatives
• medicinal chemistry
• computational chemistry